• curcumin;
  • resveratrol;
  • liposome;
  • PTEN;
  • Akt;
  • mTOR;
  • AR;
  • RNAi;
  • prostate cancer;
  • chemoprevention


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Increasing interest in the use of phytochemicals to reduce prostate cancer led us to investigate 2 potential agents, curcumin and resveratrol as preventive agents. However, there is concern about the bioavailability of these agents pertinent to the poor absorption and thereby limiting its clinical use. With the view to improve their bioavailability, we used the liposome encapsulated curcumin, and resveratrol individually and in combination in male B6C3F1/J mice. Further, we examined the chemopreventive effect of liposome encapsulated curcumin and resveratrol in combination in prostate-specific PTEN knockout mice. In vitro assays using PTEN-CaP8 cancer cells were performed to investigate the combined effects curcumin with resveratrol on (i) cell growth, apoptosis and cell cycle (ii) impact on activated p-Akt, cyclin D1, m-TOR and androgen receptor (AR) proteins involved in tumor progression. HPLC analysis of serum and prostate tissues showed a significant increase in curcumin level when liposome encapsulated curcumin coadministered with liposomal resveratrol (p < 0.001). Combination of liposomal forms of curcumin and resveratrol significantly decreased prostatic adenocarcinoma in vivo (p < 0.001). In vitro studies revealed that curcumin plus resveratrol effectively inhibit cell growth and induced apoptosis. Molecular targets activated due to the loss of phosphatase and tensin homolog (PTEN) including p-Akt, cyclin D1, mammalian target of rapamycin and AR were downregulated by these agents in combination. Findings from this study for the first time provide evidence on phytochemicals in combination to enhance chemopreventive efficacy in prostate cancer. These findings clearly suggest that phytochemicals in combination may reduce prostate cancer incidence due to the loss of the tumor suppressor gene PTEN. © 2009 UICC

Prostate cancer, one of the most common malignancies in men in the United States and in other Western countries is showing an increasing trend.1 Genetic alterations, particularly, loss of phosphatase and tensin homolog (PTEN) associated with mutation and other age-related factors is a significant risk for human prostate cancer development.2 Although chemoprevention is one of the best options for prostate cancer prevention, the influence of phytochemicals inhibiting the process of prostate carcinogenesis is not well understood, partly because of their poor bioavailability and the rate of absorption. In spite of the inconsistent reports on the bioavailability, several phytochemicals have been studied in cell culture and animal studies for their anticancer effects.3–5 Interestingly, curcumin (diferuloylmethane), one of the phenolic compounds derived from the root of the plant Curcuma longa6–8 has been shown to induce antitumor effects in several cancer types both in vitro and in vivo.9, 10 In animal studies, curcumin has been shown to increase the survival of tumor-bearing rodents by inhibiting tumor growth and impeding metastasis.11 However, there is concern about its low bioavailability and poor absorption in the gastrointestinal tract, thereby limiting its clinical use.12 Recent studies have shown that liposomal encapusulation of curcumin may enhance systemic bioavailability.13, 14

Similarly, resveratrol, a phytoalexin found in grapes and red wines has been identified as an antioxidant and antimutagen that induces Phase II drug-metabolizing enzymes, mediates anti-inflammatory effects, reduces cyclooxygenase and inhibits hydroperoxidase functions, such as antipromotion activity.15 The chemopreventive effect of resveratrol is strongly linked to the negative regulation of androgen receptor (AR) and other nuclear transcription factors.4, 16–22 The combination of curcumin with other agents to increase chemopreventive efficacy has been studied by others.23–25 However, the effect and the mechanism of liposomal curcumin in combination with liposomal resveratrol against prostate cancer have not been investigated. Although the pharmacological profiling and bioavailability of resveratrol have been studied in few preclinical models,26, 27 the relevance of the liposomal delivery of resveratrol and its in vivo effects in human is still unclear.28

To enhance the chemopreventive effect of these 2 potential agents against prostate cancer, we tested the hypothesis that liposomes encapsulated forms of resveratrol and curcumin in combination may inhibit prostate cancer by increasing their bioavailability synergistically and enhance the anticancer effects. In this study, we determined the bioavailability of liposome encapsulated curcumin and resveratrol, individually and in combination at the serum and tissue levels; then we evaluated the inhibitory effects of these agents (liposome encapsulated curcumin and resveratrol) against prostate cancer growth and progression. Further, using cell culture studies, we also investigated whether these agents in combination, decreased the rate of tumor cell growth by abrogating a close interaction between PI3K-AKT, AR and mammalian target of rapamycin (mTOR) signaling pathways of prostate cancer involving the loss of PTEN. Findings from this study may predict similar effect by these agents in human clinical studies for prostate cancer prevention or treatment.

Material and methods

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References


Curcumin and resveratrol with a purity of >98% were obtained from LKT Laboratories (St. Paul, MN) and Sigma (St. Louis, MO), respectively.

Animal study

The animals study conducted for bioavailability and chemopreventive efficacy were in accordance with the approved protocols of the New York University School of Medicine Institutional Animal Care and Use Committee (IACUC).


Liposomal preparations

To improve the bioavailability of curcumin, we used the liposomal preparations of curcumin and resveratrol, here after referred as liposomal (lipo) curcumin or liposomal (lipo) resveratrol. Briefly, the liposomal encapsulation of these curcumin or resveratrol (LKT Laboratories) were prepared with small aliquots of these agents (5 mg of each/kg/bw) by mixing with the liposomal lipid 1, 2-dimyristoyl-rac-glycero-3-phosphocholine (Sigma), as the liposomal agent in a standardized ratio as described earlier.13 By repeated analysis of the ratios ranging from 10:1 to 5:1, we determined the final ratio of 5:1 for optimal encapsulation of curcumin or resveratrol by liposomes. For combination, the lipo-curcumin and lipo-resveratrol (2.5 mg/kg/bw each) were mixed using a 3-way adjuvant mixer. The final products of these preparations were freeze dried overnight in dark, aliquoted and stored at −20°C and warmed up to room temperature just before use. For quality control, liposomal preparations and reproducibility validated following the protocols described earlier.13

In vivo administration of the agents

To determine the bioavailability, male B6C3F1/J mice, 6–8 weeks of age were obtained from Jackson Laboratory (Bar Harbor, ME) and housed in the Department animal facility. The animals were housed in cages with wood chip bedding in a temperature-controlled room (68–72°F) with 12-h light–dark cycle and relative humidity (45–55%) and were permitted free access to diet and drinking water. All the mice were allowed to acclimatize for a week and then randomly assigned to experimental and control groups (n = 3). After overnight fasting, the mice were administered with a total volume of 250 μl of the liposome encapsulated agents individually and in combination by oral gavage, as per the methods recommended for oral administration of natural compounds with appropriate modifications.29–32 Control mice received liposome alone. After the administration of the agents, animals from control and experimental groups were sacrificed at various time points of 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 and 12:00 hr by terminal CO2 asphyxiation. At the time of sacrifice, blood was collected by cardiac puncture and serum was obtained by centrifugation at 14,000 rpm and stored at −80°C until further HPLC analysis. Prostate from individual mice were microdissected and rapidly frozen in liquid nitrogen for further HPLC analysis and storage did not exceed 1 week. Previous studies have shown that these agents are stable in tissues under these conditions.30

HPLC analysis of serum and prostate tissues

The serum (200 μl) and prostate tissue (200 mg) were treated with sulfatase + β-glucorinidase for resveratrol before extraction, and for curcumin with methanol/ethyl acetate and the mixtures were centrifuged (2,800g 4°C for 15 min). The organic layers were removed twice, combined and evaporated to dryness under nitrogen. The plasma or the tissue samples were reconstituted in 500 μl of the mobile phase that composed of 55% acetonitrile and 45% citrate buffer (1% w/v citric acid solution adjusted to pH 3.0 using concentrated sodium hydroxide solution) and immediately analyzed using reversed-phase Breeze HPLC system (Waters Corporation, Milford, MA) available at the departmental analytical core facility. The Breeze HPLC, System consist of a Waters 1525 binary pump, 717 plus auto sampler with refrigeration unit, 2487 dual wavelength UV–vis detector and in-line degasser, and the results were calculated by the Breeze software version 3.2. Chromatographic separation were accomplished by injecting the processed serum sample (25 μl) into a Phenomenex Luna 4.6 ×150 mm, 5 μm C18 HPLC column (Phenomenex, Torrance, CA) set at 35°C with a flow rate of 1 ml/min. Resveratrol and liposomal curcumin were detected at wavelengths set at 325 and 428 nm, respectively, and the peak identification was done by HPLC with standard materials. Carbamazepine was used as an internal standard for resveratrol and 4-hydroxybenzophenone was used for curcumin as internal standard.31, 32 Standard curves were made using resveratrol and/or curcumin (Sigma).

In vivo efficacy of lipo-curcumin in combination with lipo-resveratrol

Generation of prostate-specific PTEN knockout (PTEN-KO) mice

Chemopreventive effect lipo-curcumin coadministered with lipo-resveratrol against prostate cancer was determined in a genetically modified prostate-specific PTEN-KO mouse model. This murine PTEN-KO model that was developed by deleting the PTEN tumor suppressor gene, specifically in the prostatic epithelium, is an established prostate cancer progression model, mimics the multistep tumorgenesis of human prostate cancer more closely.33 In this model, conditional homozygous deletion of PTEN in mouse prostate significantly shortens the latency of PINs and promotes their progression to metastatic cancer. These conditional PTEN-KO mice will be generated in-house at the department animal core facility by crossing PTENloxP/loxP mice with mice of the ARR2 probasin-cre transgenic line PB-cre4, wherein the Cre recombinase is under the control of a modified rat prostate-specific probasin promoter34, 35 as previously reported.33, 36 Briefly, the male ARR2Probasin-Cre transgenic mice obtained from the NIH/NCI mouse repository, ( were first crossed with the female B6.129S4-PTENtm1Hwu/J mice purchased from JAX Mice Services (Bar Harbor, Maine). Subsequently, cross breeding of the F1 generation offsprings resulted in homozygous deletion of PTEN in the F2 generation. PTEN deletion in these mice has been confirmed by PCR using tail DNA as described earlier.37 We used the primer sequences 5′-TCCCA GAGTTCATACCAGGA-3′ and 5′-GCAATGGCCAGTACTA GTGAAC-3′ for PCR amplification.36 Total and p-AKT (ser 473) activity in the prostate tissue lysate have been measured by Western blot analysis as described earlier.37 Only F2 male offsprings were used for the efficacy studies36 and mice with C57BL6/J background (JAX Mice Services) in which prostates were histologically normal were used as wild type control. All the mice were maintained under controlled conditions (21°C and 50% relative humidity) in a 12-h light/dark cycle and were fed with sterile irradiated food and water.

Efficacy studies

Four-weeks-old homozygous male PTEN-KO mice were randomly assigned to the experimental and control groups (n = 3). The experimental groups received lipo-curcumin (50 mg/kg/bw), lipo-resveratrol (50 mg/kg/bw) and a combination of both coadministered (25 mg/kg/bw each) by oral gavage in a total volume of 250 μl, 3 times in a week, for a period of 7 weeks. Plain liposomes were administered as lipo-control in a control group of mice. Oral treatment procedures are being used for dietary intervention studies by other investigators.38, 39 Resveratrol and lipo-curcumin doses for the present study were chosen from the dosage regimens used by earlier investigators.40–42 All the animals were inspected at least once daily to monitor their general health status and body weights were recorded twice every week. At the end of the bioassay study (after 7 weeks of treatment), all the mice were sacrificed by CO2-asphyxiation and necropsied. At the time of sacrifice, the total genitourinary (GU) tract was removed and weighed. The whole prostate was examined grossly for malignant lesions and weighed separately. The prostate was micro-dissected, weighed and fixed in 10% neutral-buffered formalin, embedded in paraffin, and 5-μm sections were used for histopathological evaluations. The prostate tumor incidence/burden was determined by examining H&E stained sections showing PIN and adenocarcinomas. The reduction in the total prostate weight, as well as the histopathological changes indicating regression of adenocarcinoma of the dorsolateral (DL) prostate in the treatment groups compared to control were recorded to determine the cancer chemopreventive effects.

In vitro assays using PTEN-CaP8 prostate cancer cells

Cell growth and treatments

To investigate the effects of curcumin in combination with resveratrol on cell growth and the underlying mechanisms, we used murine PTEN-CaP8 prostate cancer cells (kindly provided by Dr. Hong Wu, Department of Medicine, University of California, Los Angeles, CA) that were derived from the PTEN-KO mice of prostate cancer, as reported previously.33, 43 PTEN-Cap8 cells were grown and maintained in DMEM supplemented with 10% fetal bovine serum (Gibco, Invitrogen, Carlsbad, CA), 25 μg/ml bovine pituitary extract, 5 μg/ml bovine insulin, and 6 ng/ml recombinant human epidermal growth factor, as described earlier.43 We used 75% confluent cells grown in 6-well plates for trypan blue exclusion assays and/or cells grown in 96-well plates for MTT assays. For treatments, we used resveratrol (10 μM) or curcumin (10 μM) individually or resveratrol and curcumin (5 μM each) in combination.

Cell growth assays

Standard MTT and trypan blue exclusion (0.2%) assays were performed to assess cell growth inhibition as described earlier.37 Briefly, the PTEN-Cap8 cells grown in 6-well plates were treated with curcumin or resveratrol alone or in combinations for a period of 48 hr. Cells harvested (adherent and floating cells) after trypsinization were recovered by a quick centrifugation. Immediate staining of (10,000) cells/well with trypan blue enabled rapid and clear identification of dead cells with deep blue staining and the living cells with less uneven staining of the cell membrane. Total numbers of viable cells from each treatment were recorded and were compared with the untreated controls. Three independent set of experiments were performed simultaneously for each treatment.

Cell cycle analysis

To determine the effect on cell cycle regulation, treated and control PTEN-Cap8 cells were harvested after 48 hr by trypsinization and fixed in 10% neutral buffer formalin followed by fixing in 80% ethanol for 24 hr. The cells were washed in PBS and resuspended in 1 ml of 5 mg/ml of propidium iodide with 0.1% RNase A (Sigma, St. Louis, MO) in PBS to measure DNA content. After 30-min incubation at room temperature in the dark, the cells were analyzed by flow cytometry with Coulter Epic Elite ESP. Cell cycle analysis was performed as described earlier.37 To determine the significant difference in the DNA content between control and treatments, the analysis was repeated with triplicate samples.

Apoptosis detection

The PTEN-Cap8 cells were treated with curcumin or resveratrol alone or in combination for 48 hr and were harvested and stained with DAPI (4′,6-diaidine-phenylindole dihydrochloride) to detect apoptotic cells as described earlier.44 Subsequently, cells from a parallel set of similar experiments were used for Annexin-V staining (using FITC-conjugated antibody) of the membrane for phosphatidylserine externalization to detect cells in the early phase of apoptosis. An AX70 microscope (Olympus) was used to detect Annexin-V positive cells with morphological changes characteristic of apoptosis and quantified with Image-Pro plus software (Media Cybernetics, Silver Spring, MD).

Transfection assays with AR-siRNA

To determine AR gene silencing effects on the molecular targets of PTEN-CaP8 cells, we used AR gene-specific siRNA duplexes along with HiPerFect transfection reagent purchased from Qiagen (Valencia, CA). Transfection efficiency was assed by immunofluorescence and Western blot analysis for protein expression as described earlier.37 Briefly, ∼106 cells were grown in 6-well plates to reach 70% confluence. The original stock of the siRNA was resuspended in siRNA suspension buffer provided by the manufacturer. The remaining part of the RNA interference (RNAi) experiments were performed as described earlier.37 For all the biochemical and molecular target analysis, we used protein and/or RNA extracted from cells exposed to siRNA. The level of AR knockdown mediated by siRNAs was compared with that of the curcumin effect in combination with resveratrol after 48-hr treatment.

Western blot analysis

Total protein extracted form PTEN-CaP8 cells treated with curcumin and resveratrol were fractionated on a 10% SDS-PAGE as described earlier.37 Briefly, we used 50 μg of each sample protein after extraction with a buffer containing 150 mmol/l NaCl, 10 mmol/l Tris (pH 7.2), 5 mmol/l EDTA, 0.1% Triton X-100, 5% glycerol and 2% SDS in addition to a mixture of protease inhibitors (Boehringer Mannheim, Mannheim, Germany). Fractionated proteins were transferred onto polyvinylidene difluoride membranes. Standard Western blot procedure was carried out using specific monoclonal antibody (1:1,000 dilutions) to detect PTEN, p-Akt (ser-473) AR and D-type cyclins and mTOR (Santa Cruz Biotechnology, Santa Cruz, CA). The level of β-actin expression was used as reference for equal loading. Reactive protein bands were detected using the ECL kit (Amersham, Piscataway, NJ). Quantification of the reactive protein bands were performed by densitometry as described earlier.37

Statistical analysis

Serum and tissue bioavailability of the agents treated were monitored over time using repeated measures of Tukeys pairwise and time-line comparisons performed with ANOVA.45 Differences in body weight, total prostate weight, and histologically identified mPIN and adenocarcinoma of the PTEN-KO mouse prostate between treatment groups and control were compared using 1-way ANOVA followed by Tukey's multiple comparison procedure.45 Similar statistical tests were performed to determine the significance of differences between treatments pertinent to cell growth, apoptosis and other molecular biomarkers. All statistical analyses were performed using GraphPad Prism 4 software (San Diego, CA).


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Enhanced bioavailability of curcumin when coadministered with resveratrol

Lipo-curcumin has been reported to increase its systemic bioavailability in vivo in contrast to plain curcumin.13, 14 In this study, we used liposomal preparations to deliver curcumin in order to increase its bioavailability in combination with resveratrol (coadministered) in male B6C3F1/J mice. The HPLC analysis of curcumin concentrations in the serum and prostate tissue are presented in Figures 1a and 1b. The overall findings indicate an increase in the level of both lipo-resveratrol and lipo-curcumin in the serum and prostate tissue. Interestingly, oral administration of lipo-curcumin alone in mice showed serum concentration of 100 ng/ml after 1.5 hr. However, the mice that received lipo-curcumin coadministered with resveratrol, showed a higher serum concentration of curcumin 252 ng/ml; and this level was stable up to 4 hr in the range between 245–238 ng/ml in contrast to the plain curcumin (Fig. 1a). A similar analysis of the whole prostate tissue extract from these mice showed curcumin level increasing from 21 ng/ml (curcumin alone) to 151 ng/ml (lipo-curcumin) after 3 hr (>7-fold increase, p < 0.001); and this was stable up to 6 hr in the range between 151 and 148 ng/ml (Fig. 1b).

thumbnail image

Figure 1. Levels of curcumin and resveratrol recorded in the serum (a), and prostate tissue (b) were analyzed by HPLC. Serum and prostate tissue samples harvested at different time points of 30 min to 12 hr from male B6C3F1/J mice (n = 3) administered with plain liposome (0.1%), curcumin (50 mg/kg/bw), lipo-curcumin (50 mg/kg/bw), lipo-resveratrol (50 mg/kg/bw) and lipo-curcumin coadministered with lipo-resveratrol (25 mg/kg/bw for each) were analyzed by HPLC as described in the “Material and methods.” The data presented are the mean concentration of curcumin and resveratrol levels from 3 separate mice per group. A Tukeys pairwise comparison with ANOVA was performed to determine the difference between the control and treatment groups. The values of the standard deviation (± SD) are presented as error bars.

Download figure to PowerPoint

Curcumin in combination with resveratrol modulate body weight and inhibit prostate cancer incidence

An overall weight gain was observed in the control and experimental mice. The experimental mice that were administered with either lipo-curcumin or lipo-resveratrol (50 mg/kg each) and their combination (25 mg/kg) for 7 weeks showed no signs of toxicity, but had a small decrease in total weight gain as compared with the control group (Fig. 2a). Interestingly, our findings reveal that the mean GU tract and prostate weights were remarkably reduced in mice that received lipo-curcumin coadministered with resveratrol (Fig. 2b). A significant decrease in the prostate weight in the combination treatment group was associated with histological changes indicating a decrease in the tumor growth (inhibition of epithelial cell proliferation) in the DL prostate clearly indicate a decrease in the incidence of mPIN lesions and regression of adenocarcinomas (Fig. 2c). Total number of adenocarcinomas determined in the combination treatment group was reduced from 400 to 110 (p < 0.001) (Fig. 2d). It is also important to mention here for the readers that liposome alone has no effect on the tumor development or incidence or any other in vivo effect.

thumbnail image

Figure 2. (a) Effects of curcumin and resveratrol on body weight. The changes in the body weights recorded from 3 to 10 weeks in the untreated (control) and experimental groups of the mice were analyzed by pairwise and time-line comparisons. An overall weight gain was observed in the control and experimental mice. (b) Effect on the genitourinary (GU) tract/prostate weights. To determine the effect of these agents on the GU tract and prostate, total weights of the respective tissues harvested from 3 separate mice were recorded. The data presented are mean of the 3 data sets. The values of the standard deviation (± SD) are presented as error bars. Asterisk (***) indicates that a significant decrease in the prostate weight was recoded in the combination treatment group (p < 0.001), n = 3. (c) Tumor growth inhibition. H&E stained DL prostate tissue sections of 10-week-old PTEN-KO mice (n = 3) from untreated control and treatment groups were evaluated to assess the chemopreventive efficacy. Panels: (c1) untreated control with invasive adenocarcinomas; (c2) cellular changes indicating the inhibition of adenocarcinomas with lipo- resveratrol; (c3) cellular changes showing moderate inhibitory effect on adenocarcinomas by lipo-curcumin; (c4) cellular changes indicating a strong inhibition and regression of adenocarcinomas by lipo-curcumin in combination (coadministered) with lipo-resveratrol. (d) Quantification of tumor growth inhibition. Total number of adenocarcinomas observed under 10 high-power fields of control vs. treatment groups of 3 mice per group was recorded. The data presented are the mean values and standard deviation (±SD). The SD values are presented as error bars. Asterisk (***) indicates that a significant inhibitory effect was observed after treatment with lipo-curcumin in combination with lipo-resveratrol in contrast to the effect induced by single agents (p < 0.001), n = 3. [Color figure can be viewed in the online issue, which is available at]

Download figure to PowerPoint

Inhibitory effects of curcumin in combination with resveratrol on cell growth and cell cycle

To investigate the molecular mechanism(s) underlying the in vivo effects of curcumin in combination with resveratrol, we performed in vitro assays using PTEN-CaP8 cells deleted for PTEN. Cells treated with DMSO served as the vehicle control. The percentage of viable cells detected with trypan blue exclusion assay after 48 hr of treatment with curcumin in combination with resveratrol showed a significant decrease in the cell viability (p < 0.001) (Fig. 3a). An overall increase in Annexin-5 staining to detect apoptosis was also confirmed with DAPI staining simultaneously to detect nuclear DNA fragmentation indicated higher number of apoptotic cells. More than 5-fold increase (55–62%) in the rate of apoptosis was significant in cells treated with combination of these 2 agents (Fig. 3b). Interestingly, cell cycle analysis of these cells exposed to curcumin in combination with resveratrol (5 μM of each) revealed a G1 peak associated with a distinct pre-G1-peak indicative of apoptotic cells (Figs. 3c1 and 3c2).

thumbnail image

Figure 3. (a) Inhibition of PTEN-Cap8 cell growth. PTEN-CaP8 cells grown in 6-well plates were exposed to different treatments as described in the “Material and methods.” Results presented (mean ±SD) are the data generated from 3 sets of experiments using trypan blue exclusion (0.2%) assay to determine cell survival after 48 hr of treatment. Asterisk (***) indicates a significant cell growth inhibition in the combination treatment (p < 0.001). (b) Quantification of apoptotic cells. Apoptotic cells were determined using Annexin-V staining. Positively stained cells with morphological changes characteristic of early apoptosis after 48 hr of treatment (as described in the “Material and methods”) were identified and quantified based on the green signal with FITC. Apoptotic cells identified and quantified in the treated and control set of experiments are presented in the bar graph (mean ±SD). Asterisk (***) indicates a significant induction of apoptosis in the combination treatment (p < 0.001). (c1, c2) Cell cycle analysis. Flow cytometry analysis for DNA content (as described in the “Material and methods”) was performed in PTEN-Cap8 cells treated for 48 hr with the DMSO as solvent control (c1) and curcumin in combination with resveratrol (c2). Cells treated with curcumin in combination with resveratrol showed a pre-G1 peak (arrow) of apoptosis and cell growth arrest at G1-S phase. Cell cycle analysis was repeated with samples from 3 similar sets of experiments.

Download figure to PowerPoint

AR-siRNA and combination of curcumin plus resveratrol effects on cell cycle regulatory proteins

To determine whether modulation of AR is one of the mechanism(s) underlying the anticancer effect of curcumin in combination with resveratrol, we compared the AR-siRNA effects with that of the agent simultaneously. We used PTEN-Cap8 cells for RNAi experiments. After 48 hr of transfection with AR-siRNA, we observed a significant decrease in cyclin D1; and this was associated with a negative effect on cell growth. A sharp increase in the expression of the cell cycle regulatory proteins, p21 (Cip1) and p27 (cdk inhibitor) supports the view that the cell cycle regulatory proteins could be the direct targets controlled by AR and could be modulated by these agents of interest. Accordingly, the cells treated with curcumin in combination with resveratrol showed a similar effect as that of siRNA by decreasing the protein levels of AR and cyclin D1, associated with an increase in p21 and p27 (Fig. 4).

thumbnail image

Figure 4. Combination effect of curcumin with resveratrol on cell cycle regulatory proteins. (a) Western blot analysis of total protein extracted from PTEN-Cap8 cells transfected with 2 regions of the AR-siRNA and curcumin or resveratrol simultaneously in separate experiments as described in the Methods. Total protein lysates were analyzed for the protein expression of cyclin D1, cdk inhibitor p21(waf1/Cip1) and p27 (Kip1) β-actin was used as the loading control. (b) Bar graph represents the semiquantification of the corresponding protein expression of the reactive protein bands determined by the densitometric analysis. The data were generated by densitometry evaluation of reactive protein bands of cyclin D1, cdk inhibitor p21(waf1/Cip1) and p27 (Kip1) from 3 independent experiments. The data presented are the mean and the values of the standard deviation (±SD). The SD values are presented as error bars.

Download figure to PowerPoint

Curcumin in combination with resveratrol modulate AR and mTOR signaling

In this study, we further extended our analysis to investigate the effect of curcumin in combination with resveratrol, on AR/mTOR signaling pathways. Findings from Western blot analysis indicate a significant inhibitory effect induced by these agents in combination on p-Akt (ser 473), AR, cyclin D1 and mTOR proteins in PTEN-Cap8 cells with loss of PTEN (Figs. 5a and 5b). Part of these findings are consistent with our earlier reports on the single effect of resveratrol mediating gene–nutrient interactions by modulating p53, and cell cycle regulatory proteins, AR and cyclin D1 associated with growth inhibition and apoptosis in human LNCaP cells.16

thumbnail image

Figure 5. Combination effect of curcumin with resveratrol on p-AKT and AR expression. (a) Western blot analysis of the total protein extracted from PTEN-Cap8 cells treated with resveratrol, curcumin, resveratrol and curcumin in combination for 48 hr was used for standard Western blot procedure to detect the level of expression of p-Akt (ser 473), AR, cyclin D1 and mTOR proteins. β-actin was used as the loading control as described in the “Material and methods.” (b) Quantification of the corresponding protein expression presented as bar graph represents the mean values of 3 independent experiments. Semiquantification of the reactive protein bands was performed by densitometry analysis. The data presented are mean and the values of the standard deviation (±SD). The SD values are presented as error bars.

Download figure to PowerPoint


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Higher consumption of natural dietary factors has been associated with a decreased risk for cancer of GU tract.46, 47 Particularly, the potential effects of phytochemicals such as resveratrol and curcumin against prostate cancer have been already documented by us16, 48 and other investigators.49–52 However, it is not known whether these agents can modulate the genetic risk of prostate cancer and the underlying molecular targets. So far, findings from in vivo assays are not able to predict specific mechanisms because of the inconsistent findings on curcumin bioavailability.30, 53 Interestingly, recent studies are suggesting that higher concentrations of curcumin could be achieved by means of liposomal delivery.13, 14 In this study, we have shown that liposomal delivery of curcumin is effective and that this agent in combination with resveratrol (coadministered) could further increase its bioavailability and stability in the serum and tissues for a longer period, which is enough to induce anti cancer effects in mice. Based on the pharmacokinetics of curcumin in combination with resveratrol, we examined the anticancer activity determined by the rate of mPIN lesions and invasive adenocarcinoma of the DL prostate in PTEN-KO mice. Recently, modulation of prostate cancer genetic risk by dietary polyunsaturated fatty acids has been shown in PTEN-KO mice.36

Dietary administration of curcumin or resveratrol against TRAMP by other investigators has shown a significant decrease in tumor growth.22, 54 However, the doses selected in these studies are either too low (1% curcumin) or too high (625 mg of resveratrol) to compare significant biological effects. We believe that the efficacy of these agents via dietary administration could be enhanced and improved by oral administration, particularly using liposomal preparation and in combination at medium level doses that we have used in the present study. The rationale for using 50 mg of curcumin or resveratrol and half of the dose of each agent for combination in PTEN/KO model is based on its enhanced efficacy within 16-weeks period of time against prostate cancer unlike the studies conducted in TRAMP. Our findings on the enhanced bioavailability of curcumin when coadministered with resveratrol in mice further suggests a clear biological effect, possibly a synergistic interaction between these 2 phytochemicals in promoting anticancer effects. To address the question on whether resveratrol increases the bioavailability of curcumin or it is the stable lipo-curcumin that is inducing the effects, we propose several possibilities. One of the possibilities is attributed to the property of low water solubility of resveratrol; it must be bound to proteins or conjugated to remain at a higher concentration in the serum.55 We also believe that coadministration of resveratrol with lipo-curcumin may partly increase its binding with albumin in the presence of fatty acids along with curcumin.56 Albumin appears to be one of the plasmatic carriers of transporting resveratrol in blood circulation to induce biological effects. In addition, earlier studies have shown that lipo-curcumin alone modulate molecular targets and induce anticancer effects, and inhibited tumor angiogenesis in pancreatic cancer.13, 14 Our attempts to investigate the possible impact of curcumin plus resveratrol for the first time in a genetically modified mouse model for prostate cancer with loss of PTEN revealed a negative regulation of activated p-Akt, cyclin D1, AR and mTOR, suggesting that these agents can target multiple mechanism(s) of prostate carcinogenesis. Although further investigations are needed to understand more on the interactions of natural agents, our preliminary findings clearly predict the clinical relevance of these dietary components in combination to promote anticancer effects among individuals with high risk for prostate cancer due to the loss of PTEN and/or due to activated p-AKT signaling pathways.


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The authors thank Drs. Hong Wu, Department of Medicine, University of California, Los Angeles, CA, and Yong Q. Chen, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, for their expert advice on PTEN knockout mice. They acknowledge Dr. Tchou-Wong Kem-Meng for her assistance with the animal study; Mrs. Sally Lasano for her help with histology; and Mr. Al Bowers for his help with the HPLC analysis at the New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY.


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  • 1
    Jemal A,Siegel R,Ward E,Hao Y,Xu J,Murray T,Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    McMenamin ME,Soung P,Perera S,Kaplan I,Loda M,Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 42916.
  • 3
    Aggarwal BB,Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397421.
  • 4
    Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol 1997; 53: 12133.
  • 5
    Kong AN,Yu R,Hebbar V,Chen C,Owuor E,Hu R,Ee R,Mandlekar S. Signal transduction events elicited by cancer prevention compounds. Mutat Res 2001; 480–481: 23141.
  • 6
    Ammon HP,Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 17.
  • 7
    National Cancer Institute Chemoprevention Branch and Agent Development Committee. Clinical development plan: curcumin. J Cell Biochem 1996; 26S: 7285.
  • 8
    Lin JK,Pan MH,Lin-Shiau SY. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000; 13: 1538.
  • 9
    Dorai T,Cao YC,Dorai B,Buttyan R,Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001; 47: 293303.
  • 10
    Mukhopadhyay A,Bueso-Ramos C,Chatterjee D,Pantazis P,Aggarwal B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20: 7597609.
  • 11
    Menon LG,Kuttan R,Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999; 141: 15965.
  • 12
    Papahadjopoulos D,Allen TM,Gabizon A,Mayhew E,Matthay K,Huang SK,Lee KD,Woodle MC,Lasic DD,Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 114604.
  • 13
    Li L,Braiteh FS,Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 132231.
  • 14
    Li L,Ahmed B,Mehta K,Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6: 127682.
  • 15
    Jang M,Cai L,Udeani GO,Slowing KV,Thomas CF,Beecher CW,Fong HH,Farnsworth NR,Kinghorn AD,Mehta RG,Moon RC,Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 21820.
  • 16
    Narayanan BA,Re GG,Narayanan NK. Gene expression induced by resveratrol in prostate cancer cells: p53 mediated molecular targets. Int J Cancer 2003; 104: 20412.
  • 17
    Narayanan BA. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr Cancer Drug Targets 2006; 6: 71128.
  • 18
    Steele VE,Kelloff GJ,Balentine D,Boone CW,Mehta R,Bagheri D,Sigman CC,Zhu S,Sharma S. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis 2000; 21: 637.
  • 19
    Bhat KP,Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 2002; 957: 21029.
  • 20
    Harada N,Murata Y,Yamaji R,Miura T,Inui H,Nakano Y. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 55660.
  • 21
    Gill C,Walsh SE,Morrissey C,Fitzpatrick JM,Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007; 67: 164153.
  • 22
    Harper CE,Patel BB,Wang J,Arabshahi A,Eltoum IA,Lamartiniere CA. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007; 28: 194653.
  • 23
    Mann CD,Neal CP,Garcea G,Manson MM,Dennison AR,Berry DP. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 2009; 18: 1325.
  • 24
    Cheung KL,Khor TO,Kong AN. Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res 2009; 26: 22431.
  • 25
    Swamy MV,Citineni B,Patlolla JM,Mohammed A,Zhang Y,Rao CV. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer 2008; 60: 819.
  • 26
    Baur JA,Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 495506.
  • 27
    Baur JA,Pearson KJ,Price NL,Jamieson HA,Lerin C,Kalra A,Prabhu YV,Allard JS,Lopez-Lluch G,Lewis K,Pistell PJ,Poosala S, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 33742.
  • 28
    Walle T,Hsieh F,DeLegge MH,Oatis JE,Jr,Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 137782.
  • 29
    Meng X,Maliakal P,Lu H,Lee MJ,Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52: 93542.
  • 30
    Ireson CR,Jones DJ,Orr S,Coughtrie MW,Boocock DJ,Williams ML,Farmer PB,Steward WP,Gescher AJ. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 10511.
  • 31
    Horn TL,Cwik MJ,Morrissey RL,Kapetanovic I,Crowell JA,Booth TD,McCormick DL. Oncogenicity evaluation of resveratrol in p53(+/−) (p53 knockout) mice. Food Chem Toxicol 2007; 45: 5563.
  • 32
    Ma Z,Shayeganpour A,Brocks DR,Lavasanifar A,Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr 2007; 21: 54652.
  • 33
    Wang S,Gao J,Lei Q,Rozengurt N,Pritchard C,Jiao J,Thomas GV,Li G,Roy-Burman P,Nelson PS,Liu X,Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 20921.
  • 34
    Lesche R,Groszer M,Gao J,Wang Y,Messing A,Sun H,Liu X,Wu H. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002; 32: 1489.
  • 35
    Wu X,Wu J,Huang J,Powell WC,Zhang J,Matusik RJ,Sangiorgi FO,Maxson RE,Sucov HM,Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 619.
  • 36
    Berquin IM,Min Y,Wu R,Wu J,Perry D,Cline JM,Thomas MJ,Thornburg T,Kulik G,Smith A,Edwards IJ,D'Agostino R, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007; 117: 186675.
  • 37
    Narayanan BA,Narayanan NK,Davis L,Nargi D. RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 2006; 5: 111725.
  • 38
    Raina K,Singh RP,Agarwal R,Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 2007; 67: 597682.
  • 39
    Hahm ER,Arlotti JA,Marynowski SW,Singh SV. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 2008; 14: 124857.
  • 40
    Asensi M,Medina I,Ortega A,Carretero J,Bano MC,Obrador E,Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 38798.
  • 41
    Kawamori T,Lubet R,Steele VE,Kelloff GJ,Kaskey RB,Rao CV,Reddy BS. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999; 59: 597601.
  • 42
    Valentine SP,Le Nedelec MJ,Menzies AR,Scandlyn MJ,Goodin MG,Rosengren RJ. Curcumin modulates drug metabolizing enzymes in the female Swiss Webster mouse. Life Sci 2006; 78: 23918.
  • 43
    Jiao J,Wang S,Qiao R,Vivanco I,Watson PA,Sawyers CL,Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007; 67: 608391.
  • 44
    Narayanan BA,Condon MS,Bosland MC,Reddy BS,Pittman B,Narayanan NK. Suppression of N-methyl-N-nitrosourea (MNU)/testosterone-induced rat prostate cancer growth by celecoxib: effects on COX-2, cell cycle regulation and apoptosis mechanism(s). Clin Cancer Res 2003; 9: 350313.
  • 45
    Miller RG. Simultaneous statistical inference, 2nd edn. New York: Springer-Verlag, 1981; 37 p.
  • 46
    Zeegers MP,Goldbohm RA,van den Brandt PA. Consumption of vegetables and fruits and urothelial cancer incidence: a prospective study. Cancer Epidemiol Biomarkers Prev 2001; 10: 11218.
  • 47
    Nomura AM,Kolonel LN,Hankin JH,Yoshizawa CN. Dietary factors in cancer of the lower urinary tract. Int J Cancer 1991; 48: 199205.
  • 48
    Shankar S,Chen Q,Sarva K,Siddiqui I,Srivastava RK. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal 2007; 2: 10.
  • 49
    Narayanan BA,Narayanan NK,Stoner GD,Bullock BP. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci 2002; 70: 119.
  • 50
    Hong JH,Ahn KS,Bae E,Jeon SS,Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 2006; 9: 14752.
  • 51
    Deeb D,Jiang H,Gao X,Hafner MS,Wong H,Divine G,Chapman RA,Dulchavsky SA,Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-κB through suppression of IκBα phosphorylation. Mol Cancer Ther 2004; 3: 80312.
  • 52
    Wang TT,Hudson TS,Wang TC,Remsberg CM,Davies NM,Takahashi Y,Kim YS,Seifried H,Vinyard BT,Perkins SN,Hursting SD. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008; 29: 200110.
  • 53
    Araujo CC,Leon LL. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 2001; 96: 7238.
  • 54
    Barve A,Khor TO,Hao X,Keum YS,Yang CS,Reddy B,Kong AN. Murine prostate cancer inhibition by dietary phytochemicals—curcumin and phenyethylisothiocyanate. Pharm Res 2008; 25: 21819.
  • 55
    Belguendouz L,Fremont L,Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 1997; 53: 134755.
  • 56
    Jannin B,Menzel M,Berlot JP,Delmas D,Lançon A,Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004; 68: 111318.